PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Nextfin is an FCA approved aggregation and rating portal for equity and debt crowdfunding investments.
AIM is shrinking, legacy stock markets are too expensive to maintain and do not serve the requirements of SMEs, banks are closing branches, lending less and are paying little or no interest to investors. As a result of this, there is a huge growth in equity crowdfunding and P2P lending which has seen the launch of hundreds of alternative lenders & platforms that has created a new c.£3bn marketplace, expanding at 66% p.a. There is no single portal or trusted ratings index for investors to compare on a like for like basis and no secondary market to facilitate exits.
* NextFin is the new trading name of Business Agent Ltd
The solution
NextFin aggregates equity and debt crowdfunding investments to create the alternative finance marketplace. This makes it easy for investors and lenders to find and compare opportunities by presenting all investment offerings in one place. With the addition of a free of charge ratings service investors will be able to view ratings of every equity crowdfunding pitch, every P2P site, and every equity crowdfunding site. NextFin’s technology will constantly track these companies and investments providing the investor real-time intelligence on which to base investment decisions. The platforms and entrepreneurs will be self-promoting and marketing their ratings driving thousands of visitors a month to the NextFin site, in the same way, businesses refer their potential clients to Trip Advisor and Trustpilot. There is an estimated 10 million website/platform visitors per month across the whole of the alternative finance market. NextFin is targeting to direct 5% of this highly profiled traffic to its platform from which it will earn between £5-£8 per click from advertisers and partners. In addition, an in-house brokerage service also earns between 1%-6% commissions on loan placements. A future revenue stream (not featured in the financials) will be developed once visitor traffic reaches critical mass. This will see Nextfin being able to realise the full value of its captured ratings data and visitor traffic by launching a secondary market, which is estimated to be a £5bn marketplace.
NextFin is raising £500k at a pre-money valuation of £2M to: • Develop P2P and Equity site ratings• Expand the management, infrastructure and marketing resource• Increase visitor traffic to 6m a year via rating referrals
Owing to the size of the market and rapid growth of the industry, enterprise valuations in alternative finance are based on visitor traffic, market share and registered users. Recently published valuations of companies with visitor traffic of over 6m per year are in excess of £70m. NextFin is the market-leading aggregator and has first-mover advantage. It has the potential to exceed these valuations because it is the whole of the market aggregator and is currently the only ratings service provider as it grows to achieve 500,000 visitors p.m.
days to go:
Expired
investment:
£274,057
Rnwl is aiming to be the first ever over-the-top insurance platform. The company asserts that conventional insurance companies rely on a lead generation business model that is archaic and inefficient. These result in a customer's insurance options becoming an expensive and time-consuming affair. Rnwl is endeavouring to simplify this. Users can enter their credentials and requirements on the Rnwl website. The company will analyse the market and suggest the best deals for the user. Rnwl has been accepted into the Financial Conduct Authority (FCA's) Innovation Hub. It will use 74% of the investment in human resource, 14% in marketing, and 12% as operational costs.
days to go:
Expired
investment:
£450,366
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.
days to go:
Expired
investment:
£144,265
Myn is an innovative source-to-pay platform driven by AI, aiming to establish a seamless network connecting companies, workers, and recruiters. Their end-to-end solution encompasses intelligent talent sourcing, self-service talent acquisition, fully funded payrolling services, digital compliance solutions, job boards, and enticing employee benefits.
days to go:
Expired
investment:
£939,520
B-North intends to revolutionise the business lending industry, which is often outdated, impersonal and slow. The fintech company uses some of the most advanced cloud-based technology, coupled with face-to-face relationship teams to get the best lending solutions for borrowers and their businesses. The company is powered by a team with prior experience in starting and scaling challenger banks, and profitability is its focused goal. B-North has submitted the banking licence application, and the result is expected by 2020.
days to go:
Expired
investment:
£2,135,456
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
